[{"id":"a8d3d321-676b-43b3-809c-1d0358c715d7","acronym":"PEN-221-001","url":"https://clinicaltrials.gov/study/NCT02936323","created_at":"2021-02-11T16:53:16.188Z","updated_at":"2024-07-02T16:36:19.555Z","phase":"Phase 1/2","brief_title":"PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers","source_id_and_acronym":"NCT02936323 - PEN-221-001","lead_sponsor":"Tarveda Therapeutics","biomarkers":" SSTR • SSTR2","pipe":" | ","alterations":" SSTR positive • SSTR2 positive","tags":["SSTR • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nendratareotide uzatansine (PEN-221)"],"overall_status":"Completed","enrollment":" Enrollment 89","initiation":"Initiation: 12/08/2016","start_date":" 12/08/2016","primary_txt":" Primary completion: 07/31/2020","primary_completion_date":" 07/31/2020","study_txt":" Completion: 02/25/2021","study_completion_date":" 02/25/2021","last_update_posted":"2021-12-14"}]